UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 27, 2017
TRACON Pharmaceuticals, Inc. |
(Exact name of registrant as specified in its charter) |
Delaware | | 001-36818 | | 34-2037594 |
(State or other jurisdiction | | (Commission File Number) | | (IRS Employer Identification No.) |
of incorporation) | | | | |
8910 University Center Lane, Suite 700 San Diego, California | | 92122 |
(Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (858) 550-0780
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 8.01 | Other Information. |
We are providing in Exhibit 99.1, which is incorporated herein by reference, certain disclosures required by Part III of our Annual Report on Form 10-K for the year ended December 31, 2016.
Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits
Exhibit No. | | Description |
| | |
99.1 | | Form 10-K, Part III Disclosures |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | TRACON Pharmaceuticals, Inc. |
| | |
Dated: March 27, 2017 | | | | |
| | By: | | /s/ Charles P. Theuer, M.D., Ph.D. |
| | | | Charles P. Theuer, M.D., Ph.D. |
| | | | President and Chief Executive Officer |
